Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LJPC La Jolla Pharmaceutical (LJPC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About La Jolla Pharmaceutical Stock (NASDAQ:LJPC) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get LJPC alerts:Sign Up Key Stats Today's Range N/A50-Day Range$3.12▼$6.2252-Week Range N/AVolume66,708 shsAverage Volume158,476 shsMarket Capitalization$155.11 millionP/E Ratio51.84Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive LJPC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for La Jolla Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address LJPC Stock News HeadlinesInnoviva to Participate in the UBS Global Healthcare ConferenceNovember 12, 2024 | finance.yahoo.comAurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of GrowthNovember 8, 2024 | theglobeandmail.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 21, 2024 | Crypto 101 Media (Ad)Aurinia stock jumps 14% on Q3 earnings, restructuring announcementNovember 7, 2024 | msn.comInnoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024October 15, 2024 | finance.yahoo.comLongboard Pharmaceuticals Shares Hit All-Time High on Takeover by LundbeckOctober 14, 2024 | marketwatch.comH. Lundbeck to Buy Longboard Pharmaceuticals for $2.6 Billion -- UpdateOctober 14, 2024 | marketwatch.comInnoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company ProgressMay 8, 2024 | finance.yahoo.comSee More Headlines LJPC Stock Analysis - Frequently Asked Questions How were La Jolla Pharmaceutical's earnings last quarter? La Jolla Pharmaceutical (NASDAQ:LJPC) released its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of $0.01 by $0.16. The biopharmaceutical company earned $10.43 million during the quarter, compared to the consensus estimate of $13.10 million. La Jolla Pharmaceutical had a net margin of 8.54% and a negative trailing twelve-month return on equity of 5.46%. What other stocks do shareholders of La Jolla Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that La Jolla Pharmaceutical investors own include BioCryst Pharmaceuticals (BCRX), El Pollo Loco (LOCO), Intercept Pharmaceuticals (ICPT), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Sarepta Therapeutics (SRPT) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings5/16/2022Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:LJPC CUSIPN/A CIK920465 Webwww.lajollapharmaceutical.com Phone(617) 715-3600Fax858-626-2851Employees61Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.12 Trailing P/E Ratio51.84 Forward P/E RatioN/A P/E GrowthN/ANet Income$19.66 million Net Margins8.54% Pretax Margin8.64% Return on Equity-5.46% Return on Assets4.00% Debt Debt-to-Equity RatioN/A Current Ratio4.02 Quick Ratio3.52 Sales & Book Value Annual Sales$75.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow7.95 Book Value($2.94) per share Price / BookN/AMiscellaneous Outstanding Shares24,937,000Free Float15,885,000Market Cap$155.11 million OptionableOptionable Beta2.39 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:LJPC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding La Jolla Pharmaceutical Please log in to your account or sign up in order to add this asset to your watchlist. Share La Jolla Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
